Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Jovanovic

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Journal of the American College of Cardiology|September 1, 2022
Validated Model for Prediction of Adverse Cardiac Outcome in Patients With Fabry DiseaseChristopher Orsborne, Joshua Bradley, Laura J Bonnett, et al.
Trials|June 2, 2019
A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practiceRavi Vijapurapu, Rebecca Kozor, Derralynn A Hughes, et al.
Heart (British Cardiac Society)|August 26, 2019
Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathyRavi Vijapurapu, Tarekegn Geberhiwot, Ana Jovanovic, et al.
JACC. Case Reports|June 7, 2023
Inflammatory Fabry Cardiomyopathy Demonstrated Using Simultaneous [Christopher Orsborne, Jose M Anton-Rodrigez, Neal Sherratt, et al.
Molecular Genetics & Genomic Medicine|April 13, 2018
Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry studyDominique P Germain, Eva Brand, Alessandro Burlina, et al.
Molecular Genetics and Metabolism Reports|February 19, 2019
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of expertsDominique P Germain, Perry M Elliott, Bruno Falissard, et al.
ESC Heart Failure|February 27, 2020
Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysisChristoph Wanner, Ulla Feldt-Rasmussen, Ana Jovanovic, et al.
Journal of Inherited Metabolic Disease|July 20, 2024
Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registryDerralynn A Hughes, Gere Sunder-Plassmann, Ana Jovanovic, et al.
Journal of Inherited Metabolic Disease|March 19, 2020
RBCK1-related disease: A rare multisystem disorder with polyglucosan storage, auto-inflammation, recurrent infections, skeletal, and cardiac myopathy-Four additional patients and a review of the current literatureRahul Phadke, Carola Hedberg-Oldfors, Renata S Scalco, et al.
Orphanet Journal of Rare Diseases|April 29, 2018
Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trialRaphael Schiffmann, Daniel G Bichet, Ana Jovanovic, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of the American College of Cardiology|September 1, 2022
Validated Model for Prediction of Adverse Cardiac Outcome in Patients With Fabry DiseaseChristopher Orsborne, Joshua Bradley, Laura J Bonnett, et al.
Trials|June 2, 2019
A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practiceRavi Vijapurapu, Rebecca Kozor, Derralynn A Hughes, et al.
Heart (British Cardiac Society)|August 26, 2019
Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathyRavi Vijapurapu, Tarekegn Geberhiwot, Ana Jovanovic, et al.
JACC. Case Reports|June 7, 2023
Inflammatory Fabry Cardiomyopathy Demonstrated Using Simultaneous [Christopher Orsborne, Jose M Anton-Rodrigez, Neal Sherratt, et al.
Molecular Genetics & Genomic Medicine|April 13, 2018
Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry studyDominique P Germain, Eva Brand, Alessandro Burlina, et al.
Molecular Genetics and Metabolism Reports|February 19, 2019
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of expertsDominique P Germain, Perry M Elliott, Bruno Falissard, et al.
ESC Heart Failure|February 27, 2020
Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysisChristoph Wanner, Ulla Feldt-Rasmussen, Ana Jovanovic, et al.
Journal of Inherited Metabolic Disease|July 20, 2024
Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registryDerralynn A Hughes, Gere Sunder-Plassmann, Ana Jovanovic, et al.
Journal of Inherited Metabolic Disease|March 19, 2020
RBCK1-related disease: A rare multisystem disorder with polyglucosan storage, auto-inflammation, recurrent infections, skeletal, and cardiac myopathy-Four additional patients and a review of the current literatureRahul Phadke, Carola Hedberg-Oldfors, Renata S Scalco, et al.
Orphanet Journal of Rare Diseases|April 29, 2018
Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trialRaphael Schiffmann, Daniel G Bichet, Ana Jovanovic, et al.
Pageof 6